Evidence that TNF-β suppresses osteoblast differentiation of mesenchymal stem cells and resveratrol reverses it through modulation of NF-κB, Sirt1 and Runx2

It has been established that inflammation plays an important role in bone formation and bone loss. Although a lot is known about the role of TNF-alpha in bone health, very little is understood about TNF-beta, also called lymphotoxin. In this report, we examine the effect of TNF-beta on osteogenic differentiation of mesenchymal stem cells (MSCs) and its modulation by resveratrol. Monolayer and high-density cultures of MSCs were treated with osteogenic induction medium with/without TNF-beta, Sirt1 inhibitor nicotinamide (NAM), antisense oligonucleotides against Sirt1 (ASO) and/or Sirt1 stimulator resveratrol. We found that TNF-beta inhibits, in a similar way to NAM or Sirt1-ASO, the early stage of osteogenic differentiation of MSCs and this was accompanied with downregulation of bone-specific matrix, beta 1-integrin, Runx2 and with upregulation of NF-kappa B phosphorylation and NF-kappa B-regulated gene products involved in the inflammatory, degradative processes and apoptosis. However, resveratrol reversed TNF-beta- and NAM-suppressed MSCs osteogenesis by activation of Sirt1 and Runx2 that led to osteoblast differentiation. Furthermore, downregulation of Sirt1 by mRNA inhibited the effect of resveratrol, highlighting the important impact of this enzyme in the TNF-beta signaling pathway. Finally, resveratrol was able to manifest its effect both by suppression of TNF-beta-induced NF-kappa B and through direct activation of the Sirt1 and Runx2 pathway. Thus, through these studies, we present a mechanism by which a T cell-derived cytokine, TNF-beta can affect bone formation through modulation of MSCs differentiation that involves NF-kappa B, Sirt1, Runx2 and resveratrol reversed TNF-beta-promoted impairments in MSCs osteogenesis.